Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
2022-001665-12Phase 3Active
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Adjunctive KarXT with Adjunctive placebo (2 arms). Primary endpoint: Change from Baseline in PANSS Total at Week 6. Started Sep 2022; status: active.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-001665-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001665-12.